Effects of soy isoflavones on serum lipids and lipoprotein (a) in peritoneal dialysis patients.

Abstract

BACKGROUND AND AIM:

Lipid abnormalities are common in peritoneal dialysis (PD) patients and no effective treatment to decrease serum lipoprotein (a) [Lp(a)] in dialysis patients is known so far. Therefore, this research was designed to investigate the effects of soy isoflavone supplement on serum lipids and Lp(a) in PD patients.

METHODS & RESULTS:

In this randomized, double-blind, placebo-controlled trial, 40 PD patients were randomly assigned to either the isoflavone or the placebo group. The patients in the isoflavone group received 100 mg soy isoflavone daily for 8 weeks, whereas the placebo group received corresponding placebos. At baseline and the end of the 8th week, 7 mL of blood was obtained from each patient and serum triglycerides, total cholesterol, low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), and Lp(a) were measured. Serum Lp(a) reduced significantly up to 10% in the isoflavone group at the end of week 8 compared to baseline (P < 0.05), and the reduction was significant in comparison with the placebo group (P < 0.05). Serum HDL-C increased significantly up to 11.5% in the isoflavone group at the end of week 8 compared to baseline (P = 0.05), and the increment was significant in comparison with the placebo group (P < 0.05). There were no significant differences between the two groups in mean changes of serum triglycerides, total cholesterol, and LDL-C.

CONCLUSIONS:

This study indicates that daily administration of 100 mg soy isoflavones reduces serum Lp(a) and increases HDL-C concentration which are two determinants of cardiovascular disease in PD patients. CLINICALTRIALS.GOV: NCT03773029.

REGISTRATION NUMBER AND DATE:

NCT03773029 - 2018.

• Authors: Zahra Yari, Hadi Tabibi, Iraj Najafi, Mehdi Hedayati, Mina Movahedian
• Journal: Nutrition, metabolism, and cardiovascular diseases : NMCD (Nutr Metab Cardiovasc Dis) Vol. 30 Issue 8 Pg. 1382-1388 (07 24 2020) ISSN: 1590-3729 [Electronic] Netherlands
• PMID: 32513581 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Chemical References

• Biomarkers
• Cholesterol, HDL
• Isoflavones
• LPA protein, human
• Lipoprotein(a)

Topics

• Biomarkers (blood)
• Cholesterol, HDL (blood)
• Dietary Supplements (adverse effects)
• Double-Blind Method
• Female
• Humans
• Iran
• Isoflavones (administration & dosage, adverse effects, isolation & purification)
• Kidney Diseases (blood, diagnosis, therapy)
• Lipoprotein(a) (blood)
• Male
• Middle Aged
• Peritoneal Dialysis, Continuous Ambulatory (adverse effects)
• Soybeans (chemistry)
• Time Factors
• Treatment Outcome